Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

Reported median overall survival (mOS) in metastatic colorectal cancer (mCRC) patients participating in systemic therapy trials has increased to over 30 months. It is uncertain whether trial results translate to real‐life populations. Moreover, patients prefer presentation of multiple survival scena...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamers, Patricia A. H., Elferink, Marloes A. G., Stellato, Rebecca K., Punt, Cornelis J. A., May, Anne M., Koopman, Miriam, Vink, Geraldine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754475/
https://www.ncbi.nlm.nih.gov/pubmed/32638384
http://dx.doi.org/10.1002/ijc.33200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754475/
https://www.ncbi.nlm.nih.gov/pubmed/32638384
http://dx.doi.org/10.1002/ijc.33200

Ejemplares similares